TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9520191
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 1 week after RK or PRK
Study: 9520191
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B (6,000 U/ml) and 0.5% neomycin for 1 week after RK or PRK
Study: 9520191
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 15 days after LASIK
Study: 2914543
Drug: Salsalate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (1.5 g twice a day)
Study: 2914543
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (650 mg four times a day)
Study: 29058298
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation A
Study: 29058298
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation B
Study: 19840530
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose + flush + 3-minute wait + EREM
Study: 19840530
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose + flush + 10-minute wait + EREM
Study: 19840530
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose + flush + 15-minute wait + EREM
Study: 19840530
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose + 3-minute wait + EREM
Study: 11211199
Drug: Pretransplant erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretransplant erythropoietin treatment aimed at reaching a normal hemoglobin concentration (Hb) (135-160 g/liter)
Study: 11211199
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment aimed at maintaining subnormal Hb (90-120 g/liter)
Study: 104349
Drug: 0.414 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.414 g ethanol/kg body weight
Study: 30376051
Drug: Interrupted by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted by one dose strategy (IG)
Study: 27330157
Drug: ADAM17 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADAM17 inhibitor
Study: 20549501
Drug: Paracetamol 300
Normalized name: Paracetamol 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 300 mg three times daily
Study: 8882469
Drug: 12 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of low-dose CMF (100 mg CPA orally on days 1 to 14, 20 mg MTX and 500 mg 5-FU intravenously on days 1 and 8 of each cycle)
Study: 8882469
Drug: CPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA plus FT (100 mg CPA and 600 mg FT orally each day for one year)
Study: 24197291
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (1.0 μg/kg/min)
Study: 24197291
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.25 μg/kg/min)
Study: 17822506
Drug: Eflornithine 13.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine 13.9% cream
Study: 9797624
Drug: r‐HuEPO and
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO and iron (EPO + iron), 1200 IU/kg/week of r‐HuEPO plus 20 mg/kg/week of intravenous iron
Study: 2179780
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation plus less ibuprofen
Study: 2179780
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg four times a day
Study: 30844795
Drug: L-menthol spraying
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol spraying + Carbon Dioxide insufflation (n = 153)
Study: 30844795
Drug: L-menthol spraying
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol spraying + Air insufflation (n = 156)
Study: 30844795
Drug: L-menthol spraying
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol spraying
Study: 29502468
Drug: Cinitapride (CIN)
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CIN) single dose (1, 2, 4 tablets)
Study: 29502468
Drug: Cinitapride (CIN)
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CIN) multiple dose (1 mg three times a day)
Study: 29502468
Drug: Cinitapride (CIN)
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CIN) single and multiple doses
Study: 27771748
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral d-amphetamine (G/A + G/G genotypes)
Study: 26482675
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of electrographic seizures (ESG)
Study: 26482675
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of clinical seizures (CSG)
Study: 18181515
Drug: S100b levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100b levels at the end of bypass (mean 0.30 microg/L, SD +/- 0.33, range 0.00 to 1.57)
Study: 18181515
Drug: Neuropsychological battery
Normalized name: BATTERY,DISPOSABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological battery of 9 tests administered 6-8 weeks post-operatively
Study: 9863091
Drug: Jianfei Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianfei Pill (JFP)
Study: 7934346
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (2500 IU daily)
Study: 7934346
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg) and dipyridamole (100 mg 8 hourly)
Study: 22240615
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg kg(‐1)
Study: 22240615
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg kg(‐1)
Study: 21071270
Drug: Cetuximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (500 mg/m²), gemcitabine (1000 mg/m²), and oxaliplatin (100 mg/m²) every 2 weeks for 12 cycles
Study: 16358378
Drug: Low-molecular-weight-heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight-heparin (LMWH)
Study: 7815675
Drug: Magnesium diglycinate
Normalized name: azeloyl diglycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium diglycinate (100 mg dose)
Study: 2698517
Drug: Intramuscular Delagil
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Delagil therapy
Study: 970386
Drug: Histamine acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine acid phosphate at a dose of 76 mug/kg
Study: 970386
Drug: Histamine acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine acid phosphate at a dose of 3.2 mg
Study: 970386
Drug: Histamine acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine acid phosphate at various doses (40, 70, 76, 80 mug/kg and 3.2 mg)
Study: 30630341
Drug: Cangrelor (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (bolus followed by 2-hour infusion)
Study: 30630341
Drug: Placebo (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (bolus followed by 2-hour infusion)
Study: 30630341
Drug: Cangrelor and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor and Ticagrelor (180-mg loading dose administered as crushed tablets)
Study: 26839321
Drug: Betahistine 144
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 144 mg/day
Study: 22687509
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (TR-701) 200, 300, or 400 mg orally once daily for 5 to 7 days
Study: 17287635
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg once daily)
Study: 16249727
Drug: Erbium:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium:YAG laser preparation of retrograde cavities
Study: 16249727
Drug: Ultrasonic device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic device preparation of retrograde cavities
Study: 12126250
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema 2 mg/100 ml, administered twice daily (b.i.d.)
Study: 12126250
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema twice weekly
Study: 30522020
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of high‐top boots and custom made rigid contoured carbon fibre foot orthoses
Study: 22820819
Drug: Combined 830-1064
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 830-1064 nm LASER (radiating dose: 250 J cm‐2 delivered to the skin overlying the course of the median nerve at the wrist for 100 s at 25 W)
Study: 9810021
Drug: Nine children's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine children's liquid bubble bath solutions
Study: 2556807
Drug: Nebulised nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised nedocromil sodium 0.5 mg/ml
Study: 2556807
Drug: Nebulised nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised nedocromil sodium 5 mg/ml
Study: 2556807
Drug: Nebulised nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised nedocromil sodium 10 mg/ml
Study: 2556807
Drug: Nebulised nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised nedocromil sodium 20 mg/ml
Study: 2556807
Drug: Control run
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control run (no treatment)
Study: 1151647
Drug: Corn oil‐in‐water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil‐in‐water emulsion (500 mg)
Study: 1151647
Drug: Aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension (500 mg)
Study: 1151647
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A (500 mg)
Study: 1151647
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B (500 mg)
Study: 25675335
Drug: Immediate FRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate FRT therapy
Study: 25675335
Drug: Immediate VFE
Normalized name: Vfend
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate VFE therapy
Study: 25675335
Drug: Delayed FRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed FRT therapy
Study: 25675335
Drug: Delayed VFE
Normalized name: Vfend
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed VFE therapy
Study: 25675335
Drug: FRT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRT therapy
Study: 25675335
Drug: VFE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VFE therapy
Study: 21670776
Drug: Preoperative group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative group: 2g amoxycillin capsules and 1g metronidazole tablets one hour before extraction
Study: 21670776
Drug: Postoperative group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative group: 500mg amoxycillin capsules thrice daily and 400mg metronidazole tablets thrice daily for five days
Study: 16981032
Drug: Puncture in
Normalized name: tuberculin,PPD,multi-puncture INTRADERM SKIN TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puncture in the abdominal midline (Group ML)
Study: 14750201
Drug: Kan Jang
Normalized name: ASIAN GINSENG 500 mg in 500 mg ORAL CAPSULE [Cheong-Kwan-Jang Korean HongSam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kan Jang (adjuvant treatment)
Study: 14750201
Drug: Immunal (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunal (adjuvant treatment)
Study: 11384642
Drug: Micronized E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized E(2) administered by the vaginal route
Study: 11384642
Drug: Micronized E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized E(2) administered by the oral route
Study: 2961290
Drug: Low-dose nalbuphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nalbuphine 300 micrograms/kg (LN group; n = 103)
Study: 2961290
Drug: High-dose nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nalbuphine 500 micrograms/kg (HN group; n = 41)
Study: 25159356
Drug: SSM 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSM 30 µg
Study: 25159356
Drug: SSM 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSM 20 µg
Study: 23816571
Drug: Low-dose rhGH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhGH (25 μg/kg/day)
Study: 23816571
Drug: Intermediate-dose rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose rhGH (50 μg/kg/day)
Study: 23816571
Drug: High-dose rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhGH (100 μg/kg/day)
Study: 23816571
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rhGH
Study: 20718901
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200 μg/kg, single dose)
Study: 20718901
Drug: Topical malathion
Normalized name: malathion Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical malathion lotion (0.5%, single application)
Study: 18559234
Drug: Mahuang Zhisou
Normalized name: Mahuanggen (ephedra sinica)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mahuang Zhisou Capsule (MHZSC)
Study: 18559234
Drug: Mahuang Zhisou
Normalized name: Mahuanggen (ephedra sinica)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mahuang Zhisou Pill (Control)
Study: 17235418
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs including 5‐Methyltetrahydrofolate, 9‐aminocamptothecin, and others
Study: 9012325
Drug: Nitrate exposure
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate exposure (55.70-87.98 mg/l)
Study: 9012325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nitrate concentration 0.7 mg/l)
Study: 30057033
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with inhalation of odorless sweet almond oil
Study: 20045311
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment for advanced NSCLC
Study: 18532899
Drug: Naturopathic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic medicine plus usual care
Study: 12610743
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg for 14 days
Study: 8934377
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg daily) plus indapamide (2.5 mg daily)
Study: 8934377
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for patients without an indication for or contraindication to treatment with a diuretic
Study: 7450409
Drug: Nifedipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10-20 mg sublingually before each meal)
Study: 31973041
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text messages with a single item stress question
Study: 28964994
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly therapist support
Study: 28964994
Drug: Optional weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional weekly therapist support
Study: 21426323
Drug: Gamma Knife
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Knife radiosurgery (RS) at 20 Gy or 24 Gy, 5.5‐7.5 ml at the 50% isodose volume
Study: 19472126
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (placebo)
Study: 17410044
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with 40,000 U of epoetin alfa once weekly at chemotherapy initiation
Study: 17410044
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with epoetin alfa (no treatment unless Hb decreased to < 10 g/dl)
Study: 7760256
Drug: d-amphetamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.2 mg/kg)
Study: 7760256
Drug: d-amphetamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (0.4 mg/kg)
Study: 31116967
Drug: Molecular typing
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular typing and antibiotic susceptibility testing of K. pneumoniae isolates
Study: 21118604
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g for 5 days)
Study: 19234482
Drug: Tissue-cultured mountain
Normalized name: Tissue culture urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tissue-cultured mountain ginseng extract (TMGE) 1000 mg twice a day
Study: 19234482
Drug: Placebo 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1000 mg twice a day
Study: 20652398
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (arm B)
Study: 18204125
Drug: Controlled inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled inhalation of tobramycin (150 mg, twice daily for three days)
Study: 18204125
Drug: Conventional inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inhalation of tobramycin (300 mg, twice daily for three days)
Study: 10212857
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of budesonide metered dose inhaler with budesonide nasal spray
Study: 8847426
Drug: No supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplemental oxygen therapy
Study: 11755836
Drug: Estimates of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimates of horizontal cup/disk ratio from sequential full-frame photographs
Study: 2510877
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg, increased to 25 mg if needed)
Study: 2510877
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release verapamil (120 mg, increased to 240 mg if needed)
Study: 2510877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg)
Study: 2510877
Drug: Regimen V
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen V (combination treatment)
Study: 4417365
Drug: Anonymous group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anonymous group administered questionnaires
Study: 31623758
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Study: 24357450
Drug: Subfascial endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial endoscopic perforating vein surgery (SEPS) with ambulatory compression therapy
Study: 24357450
Drug: Deep vein
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep vein incompetence and treatment of superficial venous incompetence
Study: 15896236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of itraconazole alone
Study: 15896236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of itraconazole co-administered with antacid suspension
Study: 9708455
Drug: abciximab (ReoPro,
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (ReoPro, c7E3 Fab) bolus plus 12-hour infusion
Study: 9708455
Drug: bolus-plus-infusion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus-plus-infusion treatment
Study: 354732
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (pimozide)
Study: 354732
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (fluphenazine)
Study: 354732
Drug: Drug-free schizophrenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free schizophrenic patients
Study: 30045592
Drug: Thermal RF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal RF; thermal RF neurolysis was applied with a time of 60 seconds at 80º C, repeated twice after needle-tip rotation.
Study: 25573317
Drug: 2% H2
Normalized name: Hydrogen Peroxide 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% H2 inhalation for 1 h at 1 h and 6 h after CLP operation
Study: 18823458
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate (RL) solution